Stifel Nicolaus restated their buy rating on shares of Edwards Lifesciences Corporation (NYSE:EW) in a report issued on Thursday morning, MarketBeat Ratings reports. The firm currently has a $130.00 price objective on the medical research company’s stock, up from their prior price objective of $118.00.

Other equities research analysts also recently issued reports about the company. Zacks Investment Research downgraded Edwards Lifesciences Corporation from a buy rating to a hold rating in a report on Thursday, May 18th. BidaskClub downgraded Edwards Lifesciences Corporation from a strong-buy rating to a buy rating in a report on Wednesday, July 19th. Bank of America Corporation boosted their target price on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a buy rating in a report on Thursday. SunTrust Banks, Inc. boosted their target price on Edwards Lifesciences Corporation to $14.00 and gave the stock a buy rating in a report on Monday, July 17th. Finally, Royal Bank Of Canada boosted their target price on Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the stock an outperform rating in a report on Wednesday, April 26th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $121.13.

Shares of Edwards Lifesciences Corporation (EW) traded down 0.68% during mid-day trading on Thursday, hitting $114.73. The stock had a trading volume of 615,245 shares. The firm has a 50 day moving average of $117.23 and a 200 day moving average of $104.08. The stock has a market cap of $24.15 billion, a price-to-earnings ratio of 34.80 and a beta of 0.63. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. The company had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.76 earnings per share. On average, analysts forecast that Edwards Lifesciences Corporation will post $3.53 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Rating Reiterated by Stifel Nicolaus” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/edwards-lifesciences-corporation-ew-rating-reiterated-by-stifel-nicolaus/1464097.html.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 34,120 shares of the company’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $109.98, for a total transaction of $3,752,517.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $109.71, for a total transaction of $5,386,761.00. The disclosure for this sale can be found here. Insiders have sold a total of 184,951 shares of company stock valued at $20,780,242 in the last quarter. Corporate insiders own 2.13% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. M Holdings Securities Inc. purchased a new stake in Edwards Lifesciences Corporation during the fourth quarter worth approximately $381,000. Kentucky Retirement Systems purchased a new stake in Edwards Lifesciences Corporation during the fourth quarter worth approximately $1,454,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in Edwards Lifesciences Corporation during the fourth quarter worth approximately $649,000. Macquarie Group Ltd. boosted its stake in Edwards Lifesciences Corporation by 56.9% in the fourth quarter. Macquarie Group Ltd. now owns 149,380 shares of the medical research company’s stock worth $13,996,000 after buying an additional 54,196 shares in the last quarter. Finally, Bath Savings Trust Co purchased a new stake in Edwards Lifesciences Corporation during the first quarter worth approximately $229,000. Institutional investors own 83.80% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.